Navigation Links
CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
Date:9/11/2007

REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE CLOSING OF THE CLOSING OF THE SHARE EXCHANGE AGREEMENT AND THE DEVELOPMENT AND FUNDING OF THE COMPANY CONSEQUENT THEREON, AS WELL AS THE RISKS SHOWN IN THE COMPANY'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.

THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD A
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Myriad Genetics Presents Tumor Origin Technology at AACR
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
10. Myriad Genetics Presents Azixas Mode of Action at AACR
11. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... SAN DIEGO, April 30, 2015  Tandem Diabetes Care ® ... and manufacturer of the t:slim ® and t:flex™ Insulin ... March 31, 2015. In comparing the first ... , Sales grew 53 percent to $12.3 million from $8.1 ... 2,487 pumps from 1,723 pumps "Our investment in ...
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:4/30/2015)... (Nasdaq: DRRX ) announced today financial results for ... million and net loss was $4.9 million for the ... total revenues of $6.3 million and net loss of ... 2014.At March 31, 2015, we had cash and investments ... $34.9 million at December 31, 2014.  Subsequent to quarter-end, ...
Breaking Medicine Technology:Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... 2012  At the 2012 American Association of Neurological ... the Miami Beach Convention Center, Elekta (booth #725) ... Knife® Perfexion™ that promise to enhance information ... us the opportunity to demonstrate to neurological surgeons ...
... PITTSBURGH, April 13, 2012 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has received final approval from the U.S. ... Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg ... Lescol ® Capsules. This product is indicated for ...
Cached Medicine Technology:Elekta to Unveil New Neuroscience Solution for Leksell Gamma Knife at 2012 AANS Meeting 2Mylan Launches First Generic Version of Lescol® Capsules 2
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... event today, Saturday, May 2nd at the MGM Grand Garden ... able to secure tickets for both the actual fight and ... have wanted for more than five years was finally been ... step inside the ring to fight Manny “Pac-Man” Pacquiao in ...
(Date:5/2/2015)... May 02, 2015 We are pleased ... Delray Recovery Center as one of the Top Workplaces ... in the addiction treatment field for their ethics and ... innovate and to continue their educational efforts. The Delray ... environment, never forgetting their purpose – to help individuals ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious 2015 ... flagship nutritional supplement, Liquid BioCell™ Life, and the relaunch ... logo, new packaging, new products, and new messaging. ... and promote programs that serve as examples of direct ... International for their outstanding accomplishments and contributions to direct ...
(Date:5/1/2015)... NJ (PRWEB) May 01, 2015 Hope ... continued support of Hope For The Warriors® and military ... $20K to support Hope For The Warriors®, a national ... the family unit, and restoring hope for our service ... autograph signings, All American Ford collected and matched small ...
Breaking Medicine News(10 mins):Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2
... five whites could carry a genetic variant that substantially increases ... to new research. This genetic variant, characterized by one ... response to specific chemical signals. In the study, led by ... more than threefold increase in the odds that carriers will ...
... HealthDay Reporter , MONDAY, Dec. 20 (HealthDay News) -- New research ... -- contain a fatty acid that may lower the risk of ... according to the study in the Dec. 21 issue of the ... blood levels of this fatty acid reduce their odds of diabetes ...
... TUESDAY, Dec. 21 (HealthDay News) -- Judy Brown says she has ... Brown, now 51 and living in Nashua, N.H., remembers being ... come on, even though she didn,t understand at the time what ... she said. "Sometimes it would be a car, a back seat ...
... people with early stage liver cancer were more likely than ... new study from the University of Michigan Comprehensive Cancer Center. ... cancer patients were alive but only 15 percent of Hispanic ... times ranged from 10 months for whites and Hispanics to ...
... monitoring helped push cure rates to nearly 88 percent ... Research Hospital acute lymphoblastic leukemia (ALL) treatment protocol and ... battling the most common childhood cancer. A report ... of Clinical Oncology noted that overall survival jumped 30 ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... among Americans, a new study shows, despite reported links to ... safe "spray-on" tans. In fact, about one in every ... they use indoor tanning, University of Minnesota researchers report. ...
Cached Medicine News:Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 2Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 3Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 4Health News:Whole-Fat Dairy Products May Lower Type 2 Diabetes Risk: Study 2Health News:Whole-Fat Dairy Products May Lower Type 2 Diabetes Risk: Study 3Health News:A Lifetime of Migraines 2Health News:Blacks with liver cancer more likely to die, study finds 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 3Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 2Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 3
... basic Thermomixer is a compact model that ... x 1.5 ml tubes. Impressive features of ... design, and high stabilityeven at maximum mixing ... gentle to vigorous mixing, including intermittent mixing; ...
... ug Strept. 25 ug Fungizone ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
Medicine Products: